PDCD1 and neoplasm: Kuzevanova et al. [20] demonstrated that there is an increased level of TIGIT ligands on the surface of tumor cells when patients are treated with antibodies against PD-1, which may explain why anti-PD-1 alone cannot fully re-invigorate T cell and suppress disease progression in some patients.